Syed Hasan, MD
Medical Oncology · Festus, MONPI 1285086868
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AstraZeneca at 49.1% of the total. 2025 is the largest year on record at $2,279, more than ten times the $15 reported in 2020. That places this record below the midpoint for medical oncology clinicians in MO, where the typical reported total is $3,595.
Across 45 payments — averaging $90.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$254
- Pharmacyclics LLC, An Abbvie Company$235
- Incyte Corporation$177
- Beigene USA, Inc.$177
- Sanofi$150
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,67541%
- Food & beverage$2,21754%
- Education$1774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $2,000 |
| Johnson & Johnson | 4 | $254 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $235 |
| Incyte Corporation | 2 | $177 |
| Beigene USA, Inc. | 2 | $177 |
| Sanofi | 1 | $150 |
| Blueprint Medicines Corporation | 2 | $139 |
| Beone Medicines USA, Inc. | 1 | $127 |
| GSK | 1 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $98 |
| Tempus AI, Inc | 1 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $96 |
| Adaptive Biotechnologies Corporation | 1 | $86 |
| EMD Serono, Inc. | 2 | $79 |
| Merck | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Abbott | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Electromed, Inc. | 2 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Novocure Inc. | 1 | $14 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,069 in reported general payments places this provider in the 50th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 14 | $137 |
| Prednisone | 19 | $61 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Festus
- Leonid ShunyakovBolivar$2.1M
- Timothy PluardKansas City$664K
- Brad KahlSaint Louis$336K
- Michael NaughtonCape Girardeau$249K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.